Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
559 - Exactly when does a 'consumer' become a 'patient' -- is it the point at which they receive a prescription for a specific brand, or when they are dispensed a specific brand? In certain therapeutic categories (eg., epinephrine, insulin), patients receive a prescription for the molecule, which can be associated with multiple brands. At this point before a specific brand is selected, is it permissible for an HCP to expose the 'consumer/patient' to branded material, in order to facilitate brand selection? This scenario assumes that all brand options would contain the identical active molecule.
-
A patient is someone who has been instructed to take a healthcare product (e.g. someone prescribed a product) or someone for whom the HCP is considering providing such instruction and deems it appropriate to provide information about the product. It is the role of healthcare professionals to distribute health and treatment related information to patients. Given a scenario where multiple brand products contain the same active ingredient, it is at the HCPs discretion to provide the patient with information about a specific brand. As the manufacturer, you are simply providing the HCP with patient information which they may or may not choose to distribute to the patient. The key point here is that the HCP is making the decision for which brand product they are recommending. HCPs should not be instructed by manufacturers to provide information about drug X to patients on drug Y. However, the HCPs may choose to do so unprompted (that’s just medical practice).
